Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Dysphagia
Lung Cancer

Interventions: Drug: Placebo
Drug: Palifermin
Radiation: Radiotherapy
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2004-10-27

Last Posted Date: 2017-03-14

Lead Sponsor: Swedish Orphan Biovitrum

Target Recruit Count: 100

Registration Number: NCT00094861

Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer
Non-Small Cell Lung Cancer

Interventions: Biological: Panitumumab
Drug: Motesanib diphosphate
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2004-10-27

Last Posted Date: 2016-03-24

Lead Sponsor: Amgen

Target Recruit Count: 51

Registration Number: NCT00094835

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Stage IIIB Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer

Interventions: Radiation: 3-dimensional conformal radiation therapy
Drug: bortezomib
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2004-10-08

Last Posted Date: 2017-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00093756

Locations: 🇺🇸
Mcdonough District Hospital, Macomb, Illinois, United States
🇺🇸
Carle Foundation - Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Siouxland Regional Cancer Center, Sioux City, Iowa, United States

and more 139 locations

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Albumin-bound paclitaxel
Drug: Carboplatin
Drug: Herceptin®

First Posted Date: 2004-10-05

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT00093145

Locations: 🇺🇸
Swedish Medical Center Cancer Institute Research, Seattle, Washington, United States
🇺🇸
Breastlink Med Group, Long Beach, California, United States
🇺🇸
Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center, Stamford, Connecticut, United States

and more 11 locations

Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-09-16

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004172

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Phase 1

Conditions: Chronic Myeloproliferative Disorders
Drug/Agent Toxicity by Tissue/Organ
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-09-13

Last Posted Date: 2013-12-19

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 30

Registration Number: NCT00004036

Locations: 🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: gemcitabine
Drug: docetaxel
Drug: paclitaxel
Drug: vinorelbine

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 204

Registration Number: NCT00003587

Locations: 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 81 locations

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

Not Applicable

Completed

Conditions: Lung Cancer

First Posted Date: 2004-09-08

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00091039

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Lung Cancer
Neurotoxicity

First Posted Date: 2004-09-06

Last Posted Date: 2012-09-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 80

Registration Number: NCT00003072

Locations: 🇺🇸
Oncology Service of San Francisco General Hospital Medical Center, San Francisco, California, United States
🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
UCSF/Mt. Zion Cancer Center, San Francisco, California, United States

and more 1 locations

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2013-09-20

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 36

Registration Number: NCT00002616

Locations: 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy